SCbio Showcases South Carolina's Life Sciences Surge at Annual BIO Convention in Boston
Life Sciences industry generates an impressive $25 billion in annual economic impact for the Palmetto State.
South Carolina emerges as a Southeastern powerhouse in biomanufacturing, digital health, and biotech specialties.
More than 16 companies and organizations with deep roots in South Carolina will join SCbio at BIO 2025.
GREENVILLE, S.C., June 4, 2025 /PRNewswire/ -- Led by SCbio, South Carolina's unifying life sciences leader, the state's rapidly-growing life sciences industry will be on full display at BIO 2025, the annual international convention hosted by Biotechnology Innovation Organization June 16-19 in Boston.
SCbio, and more than 16 life sciences companies and organizations with roots in the Palmetto State, will showcase South Carolina's rapidly growing life sciences ecosystem and highlight the state's commitment to innovation, collaboration, and economic development in the biotech and medtech sectors. As one of the fastest-growing life sciences hubs in the Southeast, South Carolina is home to more than 1,000 life sciences companies, employing over 87,000 professionals.
SCbio's presence at BIO 2025 will serve as a platform to engage with global industry leaders, promote investment opportunities, and spotlight the talent, infrastructure, and partnerships driving life sciences growth across South Carolina. With an annual economic impact of $25.7 billion, life sciences is the fastest growing business segment in South Carolina. Since 2017, South Carolina life science jobs have grown two times the average of other southeastern states. In 2024, the South Carolina Department of Commerce recognized the life sciences as a top three business priority for economic growth. As such, the state is committed to fueling innovation, driving growth, and amplifying its position as a burgeoning leader in the advancement of life and science in unison.
"This is an incredible opportunity to tell the South Carolina story on a global stage," said James Chappell, President and CEO of SCbio. "From cutting-edge research and biomanufacturing to our workforce pipeline and pro-business climate, South Carolina has become a destination for life sciences companies looking to grow, innovate and lead the next era of health and science."
SCbio will sponsor the South Carolina pavilion at booth #447 and host events, meetings, and networking opportunities throughout the convention to foster strategic partnerships and promote the state's expanding capabilities in pharmaceuticals, biotechnology, medical devices and digital health.
The South Carolina delegation at BIO will include multiple companies and organizations from South Carolina, including BFS manufacturer Ritedose, economic development partners such as the South Carolina Department of Commerce, I-77 Alliance and others.
To schedule a meeting with the SCbio team at BIO 2025, please visit scbio.org or contact Connor Watkins, director of marketing, at cwatkins@scbio.org.
About SCbio
SCbio is the definitive, unifying leader in South Carolina's life sciences sector, fostering authentic collaboration and innovation across academia, startups, government and established enterprises. As a member-driven economic development organization, SCbio represents more than 1,000 organizations employing more than 87,000 professionals. Our members are unified by a mission to positively impact humanity through science across the ecosystem of advanced and specialty manufacturing; digital health and the data frontier; and cutting-edge health specializations. For additional information about SCbio and the life sciences industry, or to become a member, visit www.SCbio.org.
View original content to download multimedia:https://www.prnewswire.com/news-releases/scbio-showcases-south-carolinas-life-sciences-surge-at-annual-bio-convention-in-boston-302473156.html
SOURCE SCbio
Error al recuperar los datos
Inicia sesión para acceder a tu cartera de valores
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 days ago
- Associated Press
Lexaria Attending BIO International Convention
Biotechnology Sector's Premier Strategic Partnering Event KELOWNA, BC / ACCESS Newswire / June 5, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, announces that its Chief Executive Officer and President and Chief Scientific Officer will be attending the BIO International Convention ('BIO') in Boston, June 16-19. With over 1,500 exhibitors and 20,000 attendees, BIO is the largest biotechnology convention in the world. The convention provides a unique forum for networking and exploring collaborations. By participating in BIO 2025, Lexaria is seeking to advance discussions with prospective partners and strategic investors, to support the development of its clinical stage DehydraTECH® enhanced emerging drug product candidates. Lexaria is arranging a full slate of 1-on-1 meetings with global and regional corporate leaders in the fields of weight loss, diabetes and hypertension, among others. Lexaria has a limited number of meeting times still available. Interested parties are encouraged to reach out to the Company directly or via the BIO Partnering TM platform to request a meeting at BIO. About Lexaria Bioscience Corp. & DehydraTECH DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 48 patents granted and additional patents pending worldwide. For more information, please visit CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as 'anticipate,' 'if,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'could,' 'should,' 'will,' and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. INVESTOR CONTACT: George Jurcic - Head of Investor Relations [email protected] Phone: 250-765-6424, ext 202 SOURCE: Lexaria Bioscience Corp. press release
Yahoo
3 days ago
- Yahoo
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25
Dallas, Texas--(Newsfile Corp. - June 4, 2025) - Bio-Path Holdings, Inc. (OTCQB: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (OTCQB: BPTH) for Q1 2025. Bio-Path Holdings, Inc. (OTCQB: BPTH) is a clinical-stage biotechnology company based in Bellaire, Texas, pioneering RNA interference (RNAi) therapeutics through its proprietary DNAbilize® platform. This innovative technology employs neutral-charge, liposomal delivery of antisense oligonucleotides, enhancing drug stability and cellular uptake while minimizing toxicity. The Company's lead candidate, prexigebersen (BP1001), targets the Grb2 protein and is currently in Phase 2 trials for acute myeloid leukemia (AML). A modified version, BP1001-A, is undergoing Phase 1/1b trials for solid tumors and has shown promise in preclinical studies for obesity and type 2 diabetes. Another candidate, BP1002, targets the Bcl-2 protein and is being evaluated for blood cancers and solid tumors. Bio-Path is also preparing an Investigational New Drug (IND) application for BP1003, a STAT3 inhibitor aimed at treating pancreatic cancer. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Phase 2 prexigebersen data shows potential for FDA approval in AML treatment. BP1001-A trial shows early signs of efficacy in advanced solid tumors. Advancing pipeline backed by strategic R&D and a robust patent portfolio. Click image above to view full announcement. About StonegateStonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA), provides a full spectrum of investment banking services for public and private companies. Contacts: Stonegate Capital Partners (214) 987-4121 info@ Source: Stonegate, Inc. To view the source version of this press release, please visit
Yahoo
3 days ago
- Yahoo
SCbio Showcases South Carolina's Life Sciences Surge at Annual BIO Convention in Boston
Life Sciences industry generates an impressive $25 billion in annual economic impact for the Palmetto State. South Carolina emerges as a Southeastern powerhouse in biomanufacturing, digital health, and biotech specialties. More than 16 companies and organizations with deep roots in South Carolina will join SCbio at BIO 2025. GREENVILLE, S.C., June 4, 2025 /PRNewswire/ -- Led by SCbio, South Carolina's unifying life sciences leader, the state's rapidly-growing life sciences industry will be on full display at BIO 2025, the annual international convention hosted by Biotechnology Innovation Organization June 16-19 in Boston. SCbio, and more than 16 life sciences companies and organizations with roots in the Palmetto State, will showcase South Carolina's rapidly growing life sciences ecosystem and highlight the state's commitment to innovation, collaboration, and economic development in the biotech and medtech sectors. As one of the fastest-growing life sciences hubs in the Southeast, South Carolina is home to more than 1,000 life sciences companies, employing over 87,000 professionals. SCbio's presence at BIO 2025 will serve as a platform to engage with global industry leaders, promote investment opportunities, and spotlight the talent, infrastructure, and partnerships driving life sciences growth across South Carolina. With an annual economic impact of $25.7 billion, life sciences is the fastest growing business segment in South Carolina. Since 2017, South Carolina life science jobs have grown two times the average of other southeastern states. In 2024, the South Carolina Department of Commerce recognized the life sciences as a top three business priority for economic growth. As such, the state is committed to fueling innovation, driving growth, and amplifying its position as a burgeoning leader in the advancement of life and science in unison. "This is an incredible opportunity to tell the South Carolina story on a global stage," said James Chappell, President and CEO of SCbio. "From cutting-edge research and biomanufacturing to our workforce pipeline and pro-business climate, South Carolina has become a destination for life sciences companies looking to grow, innovate and lead the next era of health and science." SCbio will sponsor the South Carolina pavilion at booth #447 and host events, meetings, and networking opportunities throughout the convention to foster strategic partnerships and promote the state's expanding capabilities in pharmaceuticals, biotechnology, medical devices and digital health. The South Carolina delegation at BIO will include multiple companies and organizations from South Carolina, including BFS manufacturer Ritedose, economic development partners such as the South Carolina Department of Commerce, I-77 Alliance and others. To schedule a meeting with the SCbio team at BIO 2025, please visit or contact Connor Watkins, director of marketing, at cwatkins@ About SCbio SCbio is the definitive, unifying leader in South Carolina's life sciences sector, fostering authentic collaboration and innovation across academia, startups, government and established enterprises. As a member-driven economic development organization, SCbio represents more than 1,000 organizations employing more than 87,000 professionals. Our members are unified by a mission to positively impact humanity through science across the ecosystem of advanced and specialty manufacturing; digital health and the data frontier; and cutting-edge health specializations. For additional information about SCbio and the life sciences industry, or to become a member, visit View original content to download multimedia: SOURCE SCbio Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
